News Pfizer makes first-line case for Tukysa in breast cancer Pfizer's Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.
News Roche delivers its data reveal for adjuvant giredestrant Roche reveals the data that has it excited about giredestrant in early-stage breast cancer, but how might it be positioned versus CDK4/6 inhibitors?
News Bayer gets EU approval for menopause drug Lynkuet Bayer now has approval on both sides of the Atlantic for Lynkuet, with the EU backing it for symptoms caused by both menopause and breast cancer.
News Roche extols 'unprecedented' result with breast cancer drug Roche's oral SERD giredestrant has achieved what the company says is a stellar result as adjuvant treatment for early breast cancer.
Oncology Advances in breast cancer: What’s new from ESMO 2025 ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies worldwide.
News ESMO: Datroway, Trodelvy lay claim to frontline TNBC therapy Two TROP2-targeting drugs, Datroway and Trodelvy, have new data suggesting they could become first-line options for triple-negative breast cancer.
News CHMP decision levels the playing field for GSK's RSV jab GSK's RSV vaccine is poised for EU approval in all adults aged 18 and over, bringing it into line with rival shots from Pfizer and Moderna.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
